Abstract
Breast cancer resistance protein (BCRP) is a recently identified new member of the superfamily of ATP-binding cassette transporters. BCRP is a “half transporter” that may homo- or heterodimerize to form an active transport complex. A considerable overexpression of BCRP was reported from various atypical multidrug-resistant tumor cell lines, in particular from those which were established by treatment with mitoxantrone. Thus, BCRP represents a very interesting candidate molecule for reversal of a drug-resistant phenotype. Six hammerhead ribozymes directed against the BCRP-encoding mRNA were designed and tested for their ability to cleave their target molecule. The anti-BCRP ribozymes were in vitro synthesized using bacteriophage T7 RNA polymerase and oligonucleotide primers whereby one primer contains a T7 RNA polymerase promoter sequence. BCRP-encoding substrate RNA molecules were created by a reverse transcription polymerase chain reaction using total RNA prepared from the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV exhibiting a high BCRP mRNA expression level. One anti-BCRP ribozyme was found to show a very high endoribonucleolytic cleavage activity at physiologic pH and temperature. This ribozyme was characterized in a cell-free system with regard to its specific kinetic parameters using large target molecules. Cancer Gene Therapy (2001) 8, 185–192
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kowalski, P., Wichert, A., Holm, P. et al. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance–associated ABC transporter BCRP/MXR/ABCG2. Cancer Gene Ther 8, 185–192 (2001). https://doi.org/10.1038/sj.cgt.7700294
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700294
Keywords
This article is cited by
-
A structural analysis of in vitro catalytic activities of hammerhead ribozymes
BMC Bioinformatics (2007)
-
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)
Oncogene (2003)
-
Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2
Cancer Gene Therapy (2002)